7.5 Toxic Ingestion, Overdose & Withdrawal

7.5 Toxic Ingestion, Overdose & Withdrawal

Recognizing Toxidromes

A toxidrome is a recognizable cluster of signs and symptoms associated with a category of toxic exposure. Rapid toxidrome recognition guides both immediate treatment and antidote selection:

Activated charcoal can bind certain ingested toxins to limit systemic absorption, but it is only useful within roughly the first hour after ingestion for appropriate substances, and it is contraindicated when the airway is not protected (decreased level of consciousness with aspiration risk), for caustic/corrosive ingestions, and for most hydrocarbon ingestions.

Alcohol Withdrawal Syndrome

Alcohol withdrawal typically begins 6-24 hours after the last drink and can progress in severity — mild tremulousness and anxiety can escalate to seizures and, in the most severe cases, delirium tremens (DTs), which classically emerges 48-96 hours after the last drink and carries significant mortality risk if untreated. DTs presents with severe autonomic instability (tachycardia, hypertension, fever, diaphoresis), hallucinations, agitation, and seizure risk, and constitutes a medical emergency.

The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) scale objectively scores withdrawal severity (nausea, tremor, sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation) to drive symptom-triggered dosing. Benzodiazepines are the first-line treatment for alcohol withdrawal across the severity spectrum — they cross-react at the GABA receptor to substitute for alcohol's effect and prevent progression to seizures and DTs; dosing is titrated to the CIWA-Ar score rather than given on a fixed schedule alone in most symptom-triggered protocols.

A critical safety point: in malnourished or chronically alcohol-dependent patients, thiamine should be administered before or together with dextrose-containing fluids, not after. Giving glucose first in a thiamine-deficient patient can precipitate or worsen Wernicke encephalopathy (confusion, ataxia, ophthalmoplegia) by accelerating the metabolic demand for a vitamin the patient does not have enough of. This sequencing — thiamine before or with dextrose — is one of the most frequently tested medication-safety points in this content area.

Opioid and Other Substance Withdrawal

Opioid withdrawal is graded using the COWS (Clinical Opiate Withdrawal Scale), which assesses resting pulse, sweating, restlessness, pupil size, bone/joint aches, rhinorrhea/tearing, GI upset, tremor, yawning, anxiety, and gooseflesh skin. Unlike alcohol or benzodiazepine withdrawal, opioid withdrawal is extremely uncomfortable but is generally not life-threatening in an otherwise healthy adult — a key distinction from alcohol withdrawal, which can kill through seizures and autonomic collapse. Treatment options include buprenorphine (a partial opioid agonist that can be initiated once the patient is in mild-to-moderate withdrawal to avoid precipitated withdrawal) and clonidine to blunt the autonomic/sympathetic symptoms (tachycardia, hypertension, sweating) of withdrawal without directly treating opioid receptors.

Procedural Sedation Monitoring

Progressive care nurses frequently monitor patients receiving procedural sedation for bedside interventions. Core monitoring includes:

• Continuous capnography (end-tidal CO2) to detect hypoventilation before desaturation becomes apparent on pulse oximetry — capnography changes earlier than SpO2 in a patient breathing supplemental oxygen
• Continuous pulse oximetry
• A validated sedation scale (such as the Richmond Agitation-Sedation Scale, RASS) to titrate sedation to the intended depth and avoid oversedation
• Reversal agents readily available at the bedside — naloxone for opioid-related oversedation/respiratory depression and flumazenil for benzodiazepine-related oversedation (used selectively, since flumazenil can precipitate seizures in patients with chronic benzodiazepine use or a seizure history)

Across toxic ingestion, withdrawal, and procedural sedation content, the unifying exam theme is matching the specific antidote or scale to the specific toxin or substance — naloxone for opioids, flumazenil for benzodiazepines, atropine for cholinergic/organophosphate poisoning, CIWA-Ar for alcohol, and COWS for opioid withdrawal.

Repeat Dosing and Airway Considerations in Overdose

A key safety nuance with naloxone is that its duration of action (roughly 30-90 minutes depending on route) is often shorter than that of the opioid being reversed, particularly long-acting or high-potency agents such as methadone or fentanyl analogs. A patient who wakes after an initial dose can re-sedate and redevelop respiratory depression once the naloxone wears off, so continuous monitoring — and readiness to redose or start a naloxone infusion — is required even after an apparently successful reversal, rather than treating a single dose as definitive treatment. Airway protection takes priority over decontamination in any patient with a depressed level of consciousness: a patient who cannot protect their airway should not receive activated charcoal or be assessed for gastric decontamination until the airway is secured, since aspiration risk outweighs any benefit from limiting toxin absorption.

Providers should also keep serotonin syndrome on the differential when a patient on serotonergic medications (SSRIs, SNRIs, tramadol, certain antiemetics) presents with agitation, hyperthermia, tremor, and hyperreflexia or clonus — it can mimic other hyperadrenergic toxidromes but is managed by stopping the causative agent and providing supportive cooling and sedation rather than a specific reversal antidote.